Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience.
| Autor: | Bearz A; Medical Oncology, IRCCS, Aviano, PN, Italy. abearz@cro.it, Talamini R, Rossoni G, Santo A, de Pangher V, Fasola G, Rosetti F, Favaretto A, Gregorc V, Berretta M, Santarossa S, Berto E, Tirelli U |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | BMC research notes [BMC Res Notes] 2012 Sep 03; Vol. 5, pp. 482. Date of Electronic Publication: 2012 Sep 03. |
| DOI: | 10.1186/1756-0500-5-482 |
| Abstrakt: | Background: Although first-line therapy for patients affected by advanced mesothelioma is well established, there is a lack of data regarding the impact of second-line treatment. Methods: We retrospectively collected data of patients affected by advanced mesothelioma, already treated with first-line therapy based on pemetrexed and platin, with a response (partial response or stable disease) lasting at least 6 months, and re-treated with a pemetrexed-based therapy at progression. The primary objective was to describe time to progression and overall survival after re-treatment. Results: Overall across several Italian oncological Institutions we found 30 patients affected by advanced mesothelioma, in progression after a 6-month lasting clinical benefit following a first-line treatment with cisplatin and pemetrexed, and re-challenged with a pemetrexed-based therapy. In these patients we found a disease control rate of 66%, with reduction of pain in 43% of patients. Overall time to progression and survival were promising for a second-line setting of patients with advanced mesothelioma, being 5.1 and 13.6 months, respectively. Conclusions: In our opinion, when a patient has a long-lasting benefit from previous treatment with pemetrexed combined with a platin compound, the same treatment should be offered at progression. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|